Abstract: A display panel and a manufacture method thereof, and a display apparatus are provided. The display panel includes a first substrate and a second substrate which arranged opposite to each other. The first substrate includes a display region and a peripheral region, a conduction section is in the peripheral region of the first substrate, and the conduction section is electrically connected with a grounded section. The second substrate includes a display region and a peripheral region, a black matrix is at least in the peripheral region of the second substrate, and the black matrix is electrically connected with the conduction section.

Abstract: The present disclosure is related to a display panel. The display panel may include a first light shielding layer (101) in a display region and a second light shielding layer (212) opposite the first light shielding layer (101) in the display region. The first light shielding layer (101) may include a plurality of first openings (112), and the second light shielding layer (212) may include a plurality of second openings (222). The display region may include a middle display region (20A) and a periphery display region (20B). An area of each of the plurality of the first openings (112) in the periphery display region (20B) may be smaller than an area of each of the plurality of the first openings (112) in the middle display region (20A).

Abstract: The present invention provides De-ADCC/CDC activity monoclonal antibodies and their generation method and applications. The present invention modified the antibody sequences of multi-target sites such as PD-L1, PD-1, CTLA4, TNF-?, PCSK9, NGF, CD47 and C5. A flexible amino acid sequence was inserted between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the physical stress signal transmit from antigen-bound Fab to its Fc region to reduce the ADCC/CDC activity while not significantly increasing the formation of the polymers. The modified antibodies in the present invention and the original antibodies target the same sites, but the antibody subtype or glycosylation state is different. For the modified antibodies in the present invention, the stability is significantly improved or/and immunogenicity is significantly reduced, and the half-life is prolonged. The modified antibodies eliminate the activity of ADCC/CDC.

Abstract: The present disclosure is related to a display panel. The display panel may include a first light shielding layer (101) in a display region and a second light shielding layer (212) opposite the first light shielding layer (101) in the display region. The first light shielding layer (101) may include a plurality of first openings (112), and the second light shielding layer (212) may include a plurality of second openings (222). The display region may include a middle display region (20A) and a periphery display region (20B). An area of each of the plurality of the first openings (112) in the periphery display region (20B) may be smaller than an area of each of the plurality of the first openings (112) in the middle display region (20A).

Abstract: The present disclosure provides an array substrate and a manufacturing method thereof, a liquid crystal display panel, and a liquid crystal display apparatus, which can solve a problem that an independent backlight of the related liquid crystal display device is easy to cause light leakage, resulting in a thicker product. Both a light emitting structure and an array structure are disposed on the array substrate of the present disclosure, wherein a control device of the light emitting structure can control the light emitting source to emit light. That is, in the present disclosure, the light emitting structure is directly formed in the array substrate, which is equivalent to a built-in light emitting source, so that it is no longer necessary to adhere an external backlight, and no adhesive gap is generated to cause light leakage, and the thickness of the product can be reduced.

Abstract: Metal bioremediation and metal mining strategies can include compositions and methods.

Abstract: A method for treating autoimmune and inflammatory diseases in a human includes administering an effective amount of a low immunogenic human anti-TNF-? antibody to the human, thereby targeting TNF-?. The low immunogenic human anti-TNF-? antibody includes CDR regions of heavy and light chains from human Adalimumab, and also includes an additional human light chain amino acid sequence, and an additional human heavy chain amino acid sequence. The antibody has reduced immunogenicity compared to Adalimumab.

Abstract: A display panel and a manufacture method thereof, and a display apparatus are provided. The display panel includes a first substrate and a second substrate which arranged opposite to each other. The first substrate includes a display region and a peripheral region, a conduction section is in the peripheral region of the first substrate, and the conduction section is electrically connected with a grounded section. The second substrate includes a display region and a peripheral region, a black matrix is at least in the peripheral region of the second substrate, and the black matrix is electrically connected with the conduction section.

Abstract: The disclosure provides an array substrate, a display device, a detecting apparatus and a detecting method for detecting a defect connection of a data line. A data signal input bus of the array substrate of the present disclosure applies a data signal to each pixel unit, and a detection line is added on one side of the array substrate opposite to the data signal input bus, when the product is detected, the data signal input bus inputs the normal data signal, the detection line on the other side inputs a signal having a polarity contrary to that of the data signal. At a position of the data line existing defect connection, heat is generated and the data line is burnt at the position existing defect connection.

Abstract: Disclosed herein are low immunogenic human anti-TNF-?antibodies which can inhibit the apopotosis of cells induced by TNF-?. The invented low immunogenic human anti-TNF-? antibodies are capable of binding to TNF-? specifically. The invention presents the human anti-TNF-?antibodies which bind to TNF-? with similar affinities as Adalimumab. Most importantly, the invented human anti-TNF-? antibodies showed reduced immunogenicities in vivo, which made them safer candidate for antibody drug and other biotherapy. The invention also features method of de-immunogenicity of antibody drugs by identification, replacement of high immunogenic FR sequence(s) of the human antibody with low immunogenic FR sequences from other human IgGs, and significantly reduce the risk of human anti-human immunogenicity and improve the efficacy of antibody drugs.

Abstract: The embodiments of the present application provide a detection method and a detection device. The detection device includes: a capacitance generation circuit comprising a first capacitance electrode and a second capacitance electrode disposed opposite to each other, and a power source coupled to the first and the second capacitance electrode, the first capacitance electrode is an electrode plate, and the second capacitance electrode comprises n sub-electrodes which are provided to be insulated from each other; at least one capacitance detection circuit coupled to the electrode plate and the sub-electrodes, and configured to detect a capacitance value between the electrode plate and the sub-electrodes in response to a substrate to be tested being placed on one side of the electrode plate; and a controller configured to determine, according to the detected capacitance value, whether a foreign object exists in a region on the substrate to be tested or not.

Abstract: Metal bioremediation and metal mining strategies can include compositions and methods.

Abstract: An electrostatic test device for a display module includes: a fixing frame; an electrostatic test probe on the fixing frame; a film-stripping mechanism on the fixing frame, the film-stripping mechanism being configured to strip off a protective film on the display module; and a drive assembly configured to drive the electrostatic test probe and/or the film-stripping mechanism to move.

Abstract: Disclosed herein are humanized anti-Epidermal Growth Factor (EGF) Receptor antibodies which can inhibit the proliferation of cells expressing the EGF receptor. Humanized anti-EGFR antibodies are capable of binding to the surface of cells and killing the EGF receptor overexpression cells. The invention presents the humanized anti-EGFR antibodies which bind to different epitope and inhibit the tumor formation in a different way than Erbitux. Most importantly, once bound to the surface EGFR, these new anti-EGFR antibodies will internalize rather quickly, which made them ideal candidate for antibody drug conjugation and other biotherapy. The invention also features method of humanization which leads to 90% of the amino acid sequences are human sequence, and significantly reduce the risk of human anti-mouse immunogenicity. The present invention also demonstrated that the humanized anti-EGFR antibodies have the affinity to EGFR in the range of 2.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The present disclosure provides an array substrate and a manufacturing method thereof, a liquid crystal display panel, and a liquid crystal display apparatus, which can solve a problem that an independent backlight of the related liquid crystal display device is easy to cause light leakage, resulting in a thicker product. Both a light emitting structure and an array structure are disposed on the array substrate of the present disclosure, wherein a control device of the light emitting structure can control the light emitting source to emit light. That is, in the present disclosure, the light emitting structure is directly formed in the array substrate, which is equivalent to a built-in light emitting source, so that it is no longer necessary to adhere an external backlight, and no adhesive gap is generated to cause light leakage, and the thickness of the product can be reduced.

Abstract: A housing includes a substrate and a plastic part formed on the substrate. The substrate is made of ceramic. A plurality of holes is defined on surfaces of the substrate. The plastic part a plurality micro-structures. The plurality of holes is filled by the plurality micro-structures. A method for manufacturing the housing is provided.

Abstract: The embodiments of the present application provide a detection method and a detection device. The detection device includes: a capacitance generation circuit comprising a first capacitance electrode and a second capacitance electrode disposed opposite to each other, and a power source coupled to the first and the second capacitance electrode, the first capacitance electrode is an electrode plate, and the second capacitance electrode comprises n sub-electrodes which are provided to be insulated from each other; at least one capacitance detection circuit coupled to the electrode plate and the sub-electrodes, and configured to detect a capacitance value between the electrode plate and the sub-electrodes in response to a substrate to be tested being placed on one side of the electrode plate; and a controller configured to determine, according to the detected capacitance value, whether a foreign object exists in a region on the substrate to be tested or not.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: An electrostatic test device for a display module includes: a fixing frame; an electrostatic test probe on the fixing frame; a film-stripping mechanism on the fixing frame, the film-stripping mechanism being configured to strip off a protective film on the display module; and a drive assembly configured to drive the electrostatic test probe and/or the film-stripping mechanism to move.